How GLP-1 Medications Work
GLP-1 receptor agonists are a class of medications that have become central to medical weight management. Our medical providers may prescribe semaglutide or tirzepatide as part of an individualized appetite program. This article explains the mechanisms behind these medications, drawing on published research and FDA-reviewed data.
What is GLP-1?
GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone produced in the small intestine in response to eating. It plays several roles in metabolic regulation:
- Signals the pancreas to release insulin in a glucose-dependent manner
- Suppresses glucagon secretion, reducing glucose output from the liver
- Slows gastric emptying — food moves more slowly from the stomach to the small intestine
- Acts on the brain's hypothalamus and brainstem to reduce appetite and increase feelings of fullness
GLP-1 receptor agonists are synthetic compounds designed to mimic and amplify these effects at a longer duration than the body's naturally produced GLP-1.
How GLP-1 Receptor Agonists Reduce Appetite
The primary mechanism driving weight loss in GLP-1 programs is appetite regulation. These medications bind to GLP-1 receptors in the central nervous system — particularly in areas governing hunger and satiety — reducing overall caloric intake. Separately, slower gastric emptying means patients feel full for longer after eating.
The net effect observed in clinical trials is a meaningful reduction in body weight over time when combined with lifestyle modifications. Individual results vary based on adherence, starting weight, individual physiology, and other factors.
Semaglutide: A GLP-1 Receptor Agonist
Semaglutide is a GLP-1 receptor agonist approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adults with obesity or overweight with at least one weight-related condition. The FDA's approval is documented in the agency's press release: FDA Approves New Medication for Chronic Weight Management.
Tirzepatide: Dual GIP and GLP-1 Receptor Agonism
Tirzepatide (brand name Zepbound) acts as a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. By activating both receptor types, it targets two distinct appetite-regulating hormonal pathways simultaneously. Its FDA approval is referenced here: FDA Approves New Medication for Chronic Weight Management.
What This Means for Your Program
If you begin an appetite program with Bunny, a licensed physician will review your health history and determine whether a GLP-1 medication is medically appropriate for you. The doctor determines which specific medication — and at what dose — is right for your situation. No medication is prescribed automatically, and results vary between individuals.
All medical decisions are made solely by licensed healthcare professionals. Medications are prescribed only when medically necessary. GLP-1 medications are not suitable for everyone. Results may vary.
Results vary. Clinical trial results apply only to the FDA-approved branded medication specifically identified and do not apply to compounded medications. All medications must be prescribed by a licensed provider based on medical necessity.